Written by Lauro FigueroaValverde
Published on Vol 3 Issue 2, 2023
Prostate cancer remains the leading cause of cancer-related deaths among men globally. In 2020, Mexico’s National Institute of Statistics and Geography reported a mortality rate of 10.89 per 10,000 men aged 60 years and older due to this condition. The purpose of this study was to analyze prostate cancer-related statistical data specific to the southern region of Mexico. Mortality records from 23,527 male patients diagnosed with prostate cancer between 1979 and 2020 were reviewed using sources s
Read More
Written by Nica-Badea Delia
Published on Vol 3 Issue 2, 2023
This study investigated potential mutations in the P-53 gene in B lymphocytes from patients diagnosed with chronic lymphocytic leukemia (CLL). The expression of the p-53 protein was analyzed using the ELISA technique in twenty CLL patients across stages II-IV. In 17 out of 20 cases, the mean p-53 protein levels were 16.76 μg/dl, with a statistical probability of P = 0.034 and a coefficient of variation of 0.5%. The results showed that as CLL progresses, the amount of p-53 positive isoform protei
Read More
Written by Banyameen Iqbal
Published on Vol 3 Issue 2, 2023
Bladder cancer is a common malignancy of the urinary system, with transitional cell carcinoma (TCC) being the most common, accounting for the majority of cases (90-95%). This type of cancer typically affects people in their 60s and 70s, and men are affected significantly more often than women. Other types of bladder cancers, including epithelial and mesenchymal tumors, make up the remaining 5-10%. Squamous cell carcinoma (SCC) of the bladder is rare, contributing to only 1-3% of all bladder canc
Read More
Written by Basem T. Jamal
Published on Vol 3 Issue 2, 2023
Oral cancer (OC), the most common type of head and neck cancer, ranks as the 16th most common malignancy and the 15th leading cause of cancer-related mortality worldwide. In recent years, Saudi Arabia has seen a rise in OC incidence. Despite its prevalence, OC has one of the lowest survival rates globally, with many cases still being diagnosed at advanced stages. This study aims to evaluate the frequency of late-stage OC cases in maxillofacial surgical oncology settings in Saudi Arabia. Data wer
Read More
Written by Yashi Shrivastava
Published on Vol 3 Issue 2, 2023
Several diagnostic methods, including vital staining, autofluorescence, exfoliative cytology, and histomorphometry, have been investigated for the detection of dysplasia, although each shows different levels of sensitivity and specificity. This study aimed to investigate the role of toluidine blue in increasing the precision of histomorphometry for the detection of dysplasia in oral potentially malignant disorders (OPMDs) using exfoliative cytology. A cross-sectional, observational study was con
Read More
Written by Imane Boujguenna
Published on Vol 3 Issue 2, 2023
Granulosa cell tumors are malignant neoplasms that arise from the sexual cords and ovarian stroma. This study reviews the characteristics of 9 cases of granulosa cell tumors, with findings drawn from the existing literature. Among the cases, eight patients had adult-type granulosa tumors, while one patient had the juvenile form. The age of the patients ranged from 29 to 75 years, with a predominance of postmenopausal women (77.77%). The most common presenting symptoms were abdominal-pelvic pain
Read More
Written by C. Okoro
Published on Vol 3 Issue 2, 2023
The present study assessed the role of [18F]Fluciclovine PET/CT in detecting early recurrent prostate cancer (PCa) and its influence on treatment decisions. We retrospectively reviewed 58 [18F]Fluciclovine PET/CT scans performed for suspected early recurrence. Detection rates (DR) and semiquantitative parameters were analyzed in relation to biochemical and clinical–pathological characteristics. Clinical follow-up served as the reference standard to determine sensitivity, specificity, accuracy, a
Read More
Written by B. De Clercq
Published on Vol 3 Issue 2, 2023
Prostate cancer is a major cause of mortality among men, with about 12.5% of those diagnosed ultimately dying from the disease. Because outcomes vary substantially between low-risk and high-risk cases, identifying men at heightened risk for disease progression and death is critical. Germline genetic mutations are increasingly recognized as significant contributors to aggressive and lethal prostate cancer. This article aims to provide a comprehensive overview of management strategies for prostate
Read More
Written by J. Smith
Published on Vol 3 Issue 2, 2023
An MRI-based predictive model (MRI-PM) for estimating the likelihood of clinically significant prostate cancer (csPCa) was created and independently validated across institutions in the Barcelona metropolitan region, accompanied by an online risk calculator (RC) that enables users to define their preferred csPCa probability cut-off. The model was derived from a cohort of 1486 men undergoing 3-tesla multiparametric MRI (mpMRI) and subsequent targeted and/or systematic biopsies at a single academi
Read More
Written by H. Al-Thani
Published on Vol 3 Issue 2, 2023
Patients with head and neck cancer (HNC) frequently endure multiple distressing symptoms that can substantially compromise their quality of life. This study aimed to assess the use of nurse-led consultations (NLCs) and examine whether these interventions influenced symptom burden. We performed a retrospective review of clinical data collected in routine practice to evaluate the delivery of NLCs and monitor symptom progression using the M.D. Anderson Symptom Inventory (MDASI). The analysis includ
Read More
Written by C. Dubois
Published on Vol 3 Issue 2, 2023
Colorectal cancer (CRC) continues to rank among the most frequently diagnosed and deadliest cancers globally. Despite improvements in therapy that have extended the survival of patients with metastatic colorectal cancer (mCRC), there is still a shortage of effective biomarkers to inform treatment choices and guide clinical management. In this investigation, we employed a refined flow cytometry workflow to detect, quantify, and classify extracellular vesicles (EVs) in peripheral blood obtained fr
Read More
Written by M. Ben Salah
Published on Vol 3 Issue 2, 2023
Durvalumab has proven effective as a maintenance therapy following chemoradiotherapy in clinical trials for stage III non-small cell lung cancer (NSCLC), yet its impact in everyday clinical practice remains unclear. We conducted a multi-center observational study of veterans with stage III NSCLC to assess survival outcomes in those receiving durvalumab after chemoradiotherapy compared with patients treated with chemoradiotherapy alone. Survival analyses were performed using Kaplan–Meier estimate
Read More
Our esteemed publisher is committed to advancing medical knowledge through rigorous research dissemination. We exclusively accept submissions related to the field of medicine.
Our journals provide a platform for clinicians, researchers, and scholars to share groundbreaking discoveries, clinical insights, and evidence-based practices. By maintaining this specialized focus, we ensure that their publications contribute significantly to the advancement of healthcare worldwide.
